{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SAR231893&page=2", "query": { "intervention": "SAR231893", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SAR231893&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T00:30:26.679Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04678856", "title": "Dupilumab in CRSsNP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Rhinosinusitis Without Nasal Polyps", "Sinusitis", "Chronic Sinusitis", "Sinus Disorder", "Respiratory Disorder" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2020-12-02", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 11, "location_summary": "Roseville, California • Stockton, California • Denver, Colorado + 7 more", "locations": [ { "city": "Roseville", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Papillion", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678856" }, { "nct_id": "NCT01949311", "title": "Open-label Study of Dupilumab in Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2733, "start_date": "2013-10-10", "completion_date": "2022-06-27", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 129, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01949311" }, { "nct_id": "NCT01537640", "title": "Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "SAR231893 (REGN668) DP1", "type": "BIOLOGICAL" }, { "name": "SAR231893 (REGN668) DP2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2012-02", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-12-06", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01537640" }, { "nct_id": "NCT04180488", "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "6 Years to 80 Years" }, "enrollment_count": 397, "start_date": "2019-12-11", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 16, "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180488" }, { "nct_id": "NCT06572228", "title": "Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "ICS/LABA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2024-08-26", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 51, "location_summary": "Bakersfield, California • La Jolla, California • Lancaster, California + 47 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06572228" }, { "nct_id": "NCT02948959", "title": "Evaluation of Dupilumab in Children With Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asthma Controller Therapies", "type": "DRUG" }, { "name": "Asthma Reliever Therapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 408, "start_date": "2017-04-21", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Owensboro", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948959" }, { "nct_id": "NCT01854047", "title": "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "ICS/LABA therapy", "type": "DRUG" }, { "name": "Salbutamol/albuterol", "type": "DRUG" }, { "name": "Levosalbutamol/levalbuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2013-06", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 50, "location_summary": "Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854047" }, { "nct_id": "NCT04203797", "title": "A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "dupilumab", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2020-07-16", "completion_date": "2023-07-15", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 13, "location_summary": "Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more", "locations": [ { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04203797" }, { "nct_id": "NCT02277743", "title": "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 671, "start_date": "2014-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Clovis", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277743" }, { "nct_id": "NCT03633617", "title": "Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 321, "start_date": "2018-09-24", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-09-29T00:30:26.679Z", "location_count": 62, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633617" } ] }